Primary Myelofibrosis

Primary myelofibrosis is the most aggressive of the classic myeloproliferative neoplasms, in which a clonal stem-cell disorder drives reactive scarring (fibrosis) of the bone marrow, progressive failure of normal blood production, and a shift of hematopoiesis to the spleen and liver. It typically presents with anemia, an enlarged spleen, and constitutional symptoms, and carries the highest risk among these neoplasms of shortened survival and leukemic transformation.

Definition

Primary myelofibrosis is a Philadelphia-chromosome-negative myeloproliferative neoplasm characterized by clonal megakaryocytic and granulocytic proliferation, reactive bone marrow fibrosis, extramedullary hematopoiesis with splenomegaly, a leukoerythroblastic blood picture, and a driver mutation in JAK2, CALR, or MPL in most cases.

Scope

This entry describes primary myelofibrosis as a disease: its clonal driver mutations, the marrow fibrosis and extramedullary hematopoiesis that define it, its classification, and its prognostic stratification. It is a reference and educational topic and does not offer treatment thresholds or management advice for individual patients.

Key concepts

• Bone marrow fibrosis (reactive, cytokine-driven)
• Extramedullary hematopoiesis and splenomegaly
• Leukoerythroblastic blood film with teardrop cells
• Driver mutations (JAK2, CALR, MPL) and high-molecular-risk mutations
• Constitutional symptoms and cytokine excess
• Prognostic scoring (IPSS, DIPSS)
• Risk of leukemic transformation

Mechanisms

A clonal stem-cell mutation, most often in JAK2, CALR, or MPL, drives proliferation of abnormal megakaryocytes and granulocyte precursors and constitutive cytokine signalling (Klampfl, 2013). The abnormal megakaryocytes release growth factors that stimulate non-clonal marrow fibroblasts to deposit reticulin and collagen, so the fibrosis is a reactive, secondary response rather than a clonal change in the fibroblasts themselves. As the marrow becomes fibrotic and fails, blood production relocates to the spleen and liver, producing extramedullary hematopoiesis, massive splenomegaly, and a leukoerythroblastic blood film with characteristic teardrop-shaped red cells. Excess inflammatory cytokines underlie the prominent constitutional symptoms, and additional high-molecular-risk mutations promote progression toward marrow failure or acute leukemia.

Clinical relevance

Primary myelofibrosis is an important cause of unexplained anemia with marked splenomegaly and a leukoerythroblastic blood picture, and its recognition depends on integrating the blood film, a marrow biopsy showing fibrosis, and driver-mutation testing. This entry explains the disease and its prognosis for reference; it does not provide treatment thresholds or management recommendations for individuals.

Epidemiology

Primary myelofibrosis is the least common of the three classic myeloproliferative neoplasms, with an incidence on the order of roughly one or fewer cases per hundred thousand people per year and a median age at diagnosis around the mid-sixties to seventies. Among these neoplasms it carries the shortest median survival and the highest risk of progression to acute leukemia, though outcomes vary widely by prognostic group.

Evidence & guidelines

Diagnosis follows World Health Organization criteria integrating marrow fibrosis grade, megakaryocyte morphology, a clonal driver mutation, and exclusion of other myeloid neoplasms. Prognosis is stratified with the International Prognostic Scoring System and its dynamic form, which weigh age, anemia, leukocytosis, circulating blasts, and constitutional symptoms (Cervantes, 2009; Passamonti, 2010). Two randomized trials of the JAK inhibitor ruxolitinib showed reductions in spleen size and symptom burden, establishing JAK inhibition as a central therapeutic principle (Verstovsek, 2012; Harrison, 2012).

History

Long known under names such as agnogenic myeloid metaplasia and chronic idiopathic myelofibrosis, the disease was understood clinically by its marrow fibrosis, splenomegaly, and teardrop-cell blood film. Molecular insight came with the discovery of JAK2 and later CALR mutations among the myeloproliferative neoplasms (Klampfl, 2013). Prognostic models developed by international working groups (Cervantes, 2009; Passamonti, 2010) and randomized JAK-inhibitor trials (Verstovsek, 2012; Harrison, 2012) shaped the modern framework for assessing and treating the disease.

Debates

What does JAK inhibition achieve in primary myelofibrosis?

Randomized trials show that ruxolitinib reduces spleen size and symptom burden, but whether and how much it modifies the underlying clone and overall survival has been debated, framing it as predominantly disease-modifying for symptoms rather than curative.

Key figures

• Francisco Cervantes
• Francesco Passamonti
• Srdan Verstovsek
• Claire Harrison
• Thorsten Klampfl

Seminal works

• cervantes-2009
• passamonti-2010
• verstovsek-2012
• harrison-2012

Frequently asked questions

Is the bone marrow scarring in myelofibrosis itself the cancer?

No. The fibrosis is a reactive, secondary response by non-clonal fibroblasts to factors released by the abnormal clonal megakaryocytes; the malignant clone is the hematopoietic stem-cell population, not the scar tissue.

Why do patients with myelofibrosis often have a very large spleen?

As the fibrotic marrow fails, blood production shifts to the spleen and liver, a process called extramedullary hematopoiesis, which causes the spleen to enlarge, sometimes massively.